Optimal intertemporal curative drug expenses: The case of hepatitis C in France

We study intertemporal tradeoffs that health authorities face when considering the control of an epidemic using innovative curative medical treatments. We set up a dynamically controlled susceptible–infected–recovered (SIR) model for an epidemic in which patients can be asymptomatic, and we analyze...

Full description

Saved in:
Bibliographic Details
Published in:Journal of health economics 2024-03, Vol.94, p.102861-102861, Article 102861
Main Authors: Dubois, Pierre, Magnac, Thierry
Format: Article
Language:English
Subjects:
Budgets
Controlled epidemic dynamics
Economics and Finance
Epidemics
France - epidemiology
Hepatitis C
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Humanities and Social Sciences
Humans
Life Sciences
Optimal intertemporal policies
Pharmaceuticals
Santé publique et épidémiologie
SIR model
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c407t-ed13f3a8aa9ca0a8cba35049048eb01523fbc639e964433b1a59d32917386ab3
container_end_page 102861
container_issue
container_start_page 102861
container_title Journal of health economics
container_volume 94
creator Dubois, Pierre
Magnac, Thierry
description We study intertemporal tradeoffs that health authorities face when considering the control of an epidemic using innovative curative medical treatments. We set up a dynamically controlled susceptible–infected–recovered (SIR) model for an epidemic in which patients can be asymptomatic, and we analyze the optimality conditions of the sequence of cure expenses decided by health authorities at the onset of the drug innovation process. We show that analytical conclusions are ambiguous because of their dependence on parameter values. As an application, we focus on the case study of hepatitis C, the treatment for which underwent a major upheaval when curative drugs were introduced in 2014. We calibrate our controlled SIR model using French data and simulate optimal policies. We show that the optimal policy entails some front loading of the intertemporal budget. The analysis demonstrates how beneficial intertemporal budgeting can be compared to non-forward-looking constant budget allocation.
doi_str_mv 10.1016/j.jhealeco.2024.102861
format article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04501256v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167629624000067</els_id><sourcerecordid>2928242475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-ed13f3a8aa9ca0a8cba35049048eb01523fbc639e964433b1a59d32917386ab3</originalsourceid><addsrcrecordid>eNqFkM1O6zAQRi0Egl7gFZCXsEjxX5yYFaiCy5UqddO9NXEm1FXaBDup4O1xFWB7Z2PN6Hwz8iHkhrM5Z1zfb-fbDUKLrpsLJlQailLzEzLjZWEyrpU-JbMEFpkWRl-QPzFuWapcmnNyIUupC5WLGVmt-sHvoKV-P2AYcNd3IXVuDDD4A9I6jG8UP3rcR4wPdL1B6iAi7Rq6wT4xg490kdL0JcDe4RU5a6CNeP39XpL1y_N68ZotV3__LZ6WmVOsGDKsuWwklADGAYPSVSBzpgxTJVaM50I2ldPSoNFKSVlxyE0theGFLDVU8pLcTWs30No-pB-ET9uBt69PS3ucMZUzLnJ94Im9ndg-dO8jxsHufHTYtrDHboxWGFEKJVSRJ1RPqAtdjAGb392c2aN3u7U_3u3Ru528p-DN942x2mH9G_sRnYDHCcAk5eAx2Og8JmG1D-gGW3f-fze-AJ-alZk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2928242475</pqid></control><display><type>article</type><title>Optimal intertemporal curative drug expenses: The case of hepatitis C in France</title><source>ScienceDirect Journals</source><creator>Dubois, Pierre ; Magnac, Thierry</creator><creatorcontrib>Dubois, Pierre ; Magnac, Thierry</creatorcontrib><description>We study intertemporal tradeoffs that health authorities face when considering the control of an epidemic using innovative curative medical treatments. We set up a dynamically controlled susceptible–infected–recovered (SIR) model for an epidemic in which patients can be asymptomatic, and we analyze the optimality conditions of the sequence of cure expenses decided by health authorities at the onset of the drug innovation process. We show that analytical conclusions are ambiguous because of their dependence on parameter values. As an application, we focus on the case study of hepatitis C, the treatment for which underwent a major upheaval when curative drugs were introduced in 2014. We calibrate our controlled SIR model using French data and simulate optimal policies. We show that the optimal policy entails some front loading of the intertemporal budget. The analysis demonstrates how beneficial intertemporal budgeting can be compared to non-forward-looking constant budget allocation.</description><identifier>ISSN: 0167-6296</identifier><identifier>EISSN: 1879-1646</identifier><identifier>DOI: 10.1016/j.jhealeco.2024.102861</identifier><identifier>PMID: 38367452</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Budgets ; Controlled epidemic dynamics ; Economics and Finance ; Epidemics ; France - epidemiology ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatitis C - epidemiology ; Humanities and Social Sciences ; Humans ; Life Sciences ; Optimal intertemporal policies ; Pharmaceuticals ; Santé publique et épidémiologie ; SIR model</subject><ispartof>Journal of health economics, 2024-03, Vol.94, p.102861-102861, Article 102861</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c407t-ed13f3a8aa9ca0a8cba35049048eb01523fbc639e964433b1a59d32917386ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38367452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04501256$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Dubois, Pierre</creatorcontrib><creatorcontrib>Magnac, Thierry</creatorcontrib><title>Optimal intertemporal curative drug expenses: The case of hepatitis C in France</title><title>Journal of health economics</title><addtitle>J Health Econ</addtitle><description>We study intertemporal tradeoffs that health authorities face when considering the control of an epidemic using innovative curative medical treatments. We set up a dynamically controlled susceptible–infected–recovered (SIR) model for an epidemic in which patients can be asymptomatic, and we analyze the optimality conditions of the sequence of cure expenses decided by health authorities at the onset of the drug innovation process. We show that analytical conclusions are ambiguous because of their dependence on parameter values. As an application, we focus on the case study of hepatitis C, the treatment for which underwent a major upheaval when curative drugs were introduced in 2014. We calibrate our controlled SIR model using French data and simulate optimal policies. We show that the optimal policy entails some front loading of the intertemporal budget. The analysis demonstrates how beneficial intertemporal budgeting can be compared to non-forward-looking constant budget allocation.</description><subject>Budgets</subject><subject>Controlled epidemic dynamics</subject><subject>Economics and Finance</subject><subject>Epidemics</subject><subject>France - epidemiology</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - epidemiology</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Optimal intertemporal policies</subject><subject>Pharmaceuticals</subject><subject>Santé publique et épidémiologie</subject><subject>SIR model</subject><issn>0167-6296</issn><issn>1879-1646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkM1O6zAQRi0Egl7gFZCXsEjxX5yYFaiCy5UqddO9NXEm1FXaBDup4O1xFWB7Z2PN6Hwz8iHkhrM5Z1zfb-fbDUKLrpsLJlQailLzEzLjZWEyrpU-JbMEFpkWRl-QPzFuWapcmnNyIUupC5WLGVmt-sHvoKV-P2AYcNd3IXVuDDD4A9I6jG8UP3rcR4wPdL1B6iAi7Rq6wT4xg490kdL0JcDe4RU5a6CNeP39XpL1y_N68ZotV3__LZ6WmVOsGDKsuWwklADGAYPSVSBzpgxTJVaM50I2ldPSoNFKSVlxyE0theGFLDVU8pLcTWs30No-pB-ET9uBt69PS3ucMZUzLnJ94Im9ndg-dO8jxsHufHTYtrDHboxWGFEKJVSRJ1RPqAtdjAGb392c2aN3u7U_3u3Ru528p-DN942x2mH9G_sRnYDHCcAk5eAx2Og8JmG1D-gGW3f-fze-AJ-alZk</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Dubois, Pierre</creator><creator>Magnac, Thierry</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>BXJBU</scope><scope>IHQJB</scope><scope>VOOES</scope></search><sort><creationdate>20240301</creationdate><title>Optimal intertemporal curative drug expenses: The case of hepatitis C in France</title><author>Dubois, Pierre ; Magnac, Thierry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-ed13f3a8aa9ca0a8cba35049048eb01523fbc639e964433b1a59d32917386ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Budgets</topic><topic>Controlled epidemic dynamics</topic><topic>Economics and Finance</topic><topic>Epidemics</topic><topic>France - epidemiology</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - epidemiology</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Optimal intertemporal policies</topic><topic>Pharmaceuticals</topic><topic>Santé publique et épidémiologie</topic><topic>SIR model</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dubois, Pierre</creatorcontrib><creatorcontrib>Magnac, Thierry</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société</collection><collection>HAL-SHS: Archive ouverte en Sciences de l'Homme et de la Société (Open Access)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Journal of health economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dubois, Pierre</au><au>Magnac, Thierry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal intertemporal curative drug expenses: The case of hepatitis C in France</atitle><jtitle>Journal of health economics</jtitle><addtitle>J Health Econ</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>94</volume><spage>102861</spage><epage>102861</epage><pages>102861-102861</pages><artnum>102861</artnum><issn>0167-6296</issn><eissn>1879-1646</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>We study intertemporal tradeoffs that health authorities face when considering the control of an epidemic using innovative curative medical treatments. We set up a dynamically controlled susceptible–infected–recovered (SIR) model for an epidemic in which patients can be asymptomatic, and we analyze the optimality conditions of the sequence of cure expenses decided by health authorities at the onset of the drug innovation process. We show that analytical conclusions are ambiguous because of their dependence on parameter values. As an application, we focus on the case study of hepatitis C, the treatment for which underwent a major upheaval when curative drugs were introduced in 2014. We calibrate our controlled SIR model using French data and simulate optimal policies. We show that the optimal policy entails some front loading of the intertemporal budget. The analysis demonstrates how beneficial intertemporal budgeting can be compared to non-forward-looking constant budget allocation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38367452</pmid><doi>10.1016/j.jhealeco.2024.102861</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-6296
ispartof Journal of health economics, 2024-03, Vol.94, p.102861-102861, Article 102861
issn 0167-6296
1879-1646
language eng
recordid cdi_hal_primary_oai_HAL_hal_04501256v1
source ScienceDirect Journals
subjects Budgets
Controlled epidemic dynamics
Economics and Finance
Epidemics
France - epidemiology
Hepatitis C
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Humanities and Social Sciences
Humans
Life Sciences
Optimal intertemporal policies
Pharmaceuticals
Santé publique et épidémiologie
SIR model
title Optimal intertemporal curative drug expenses: The case of hepatitis C in France
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T22%3A44%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20intertemporal%20curative%20drug%20expenses:%20The%20case%20of%20hepatitis%20C%20in%20France&rft.jtitle=Journal%20of%20health%20economics&rft.au=Dubois,%20Pierre&rft.date=2024-03-01&rft.volume=94&rft.spage=102861&rft.epage=102861&rft.pages=102861-102861&rft.artnum=102861&rft.issn=0167-6296&rft.eissn=1879-1646&rft_id=info:doi/10.1016/j.jhealeco.2024.102861&rft_dat=%3Cproquest_hal_p%3E2928242475%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c407t-ed13f3a8aa9ca0a8cba35049048eb01523fbc639e964433b1a59d32917386ab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2928242475&rft_id=info:pmid/38367452&rfr_iscdi=true